XNAS 09 Oct, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.48 per share. | 04 Aug 2026 | 30,000 | 54,645 (0%) | 0% | 30.5 | 914,400 | Common stock |
| Dr. Jay T. Backstrom, M.D.,M.P.H. | Director | 08 Jul 2026 | 1,447 | 2,894 | - | - | Restricted stock units | ||
| Dr. Jay T. Backstrom, M.D.,M.P.H. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2026 | 1,447 | 1,447 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.56 per share. | 01 Jul 2026 | 4,007 | 84,645 (0%) | 0% | 37.6 | 150,503 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 8,375 | 88,652 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Jul 2026 | 8,375 | 0 | - | - | Restricted stock units | ||
| Mr. Jeffrey D. Capello | Director | 18 Jun 2026 | 2,927 | 2,927 | - | - | Restricted stock units | ||
| Mr. Jeffrey D. Capello | Director | 18 Jun 2026 | 14,950 | 14,950 | - | - | Stock options (right to buy) | ||
| Mr. Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2026 | 2,816 | 10,865 (0%) | 0% | 0 | Common stock | |
| Mr. Jeffrey D. Capello | Director | 18 Jun 2026 | 2,816 | 0 | - | - | Restricted stock units | ||
| Ms. Kaye Foster | Director | 18 Jun 2026 | 2,816 | 0 | - | - | Restricted stock units | ||
| Ms. Kaye Foster | Director | 18 Jun 2026 | 14,950 | 14,950 | - | - | Stock options (right to buy) | ||
| Ms. Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2026 | 2,816 | 10,284 (0%) | 0% | 0 | Common stock | |
| Ms. Kaye Foster | Director | 18 Jun 2026 | 2,927 | 2,927 | - | - | Restricted stock units | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | 18 Jun 2026 | 2,816 | 0 | - | - | Restricted stock units | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | 18 Jun 2026 | 2,927 | 2,927 | - | - | Restricted stock units | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | 18 Jun 2026 | 14,950 | 14,950 | - | - | Stock options (right to buy) | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2026 | 2,816 | 154,156 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | 18 Jun 2026 | 39,000 | 39,000 | - | - | Performance share units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | 18 Jun 2026 | 39,000 | 39,000 | - | - | Restricted stock units | ||
| Ms. Cynthia Smith | Director | 18 Jun 2026 | 14,950 | 14,950 | - | - | Stock options (right to buy) | ||
| Ms. Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2026 | 2,816 | 15,230 (0%) | 0% | 0 | Common stock | |
| Ms. Cynthia Smith | Director | 18 Jun 2026 | 2,816 | 0 | - | - | Restricted stock units | ||
| Ms. Cynthia Smith | Director | 18 Jun 2026 | 2,927 | 2,927 | - | - | Restricted stock units | ||
| Dr. Maykin Ho, PhD | Director | 18 Jun 2026 | 2,927 | 2,927 | - | - | Restricted stock units | ||
| Dr. Maykin Ho, PhD | Director | 18 Jun 2026 | 14,950 | 14,950 | - | - | Stock options (right to buy) | ||
| Dr. Maykin Ho, PhD | Director | 18 Jun 2026 | 2,816 | 0 | - | - | Restricted stock units | ||
| Dr. Maykin Ho, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2026 | 2,816 | 19,848 (0%) | 0% | 0 | Common stock | |
| Dr. David T. Scadden, M.D. | Director | 18 Jun 2026 | 2,816 | 0 | - | - | Restricted stock units | ||
| Dr. David T. Scadden, M.D. | Director | 18 Jun 2026 | 14,950 | 14,950 | - | - | Stock options (right to buy) | ||
| Dr. David T. Scadden, M.D. | Director | 18 Jun 2026 | 2,927 | 2,927 | - | - | Restricted stock units | ||
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2026 | 2,816 | 20,419 (0%) | 0% | 0 | Common stock | |
| Dr. Jay T. Backstrom, M.D.,M.P.H. | Director | 18 Jun 2026 | 2,927 | 2,927 | - | - | Restricted stock units | ||
| Dr. Jay T. Backstrom, M.D.,M.P.H. | Director | 18 Jun 2026 | 14,950 | 14,950 | - | - | Stock options (right to buy) | ||
| Dr. Rahul D. Ballal, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2026 | 2,816 | 15,230 (0%) | 0% | 0 | Common stock | |
| Dr. Rahul D. Ballal, PhD | Director | 18 Jun 2026 | 2,816 | 0 | - | - | Restricted stock units | ||
| Dr. Rahul D. Ballal, PhD | Director | 18 Jun 2026 | 2,927 | 2,927 | - | - | Restricted stock units | ||
| Dr. Rahul D. Ballal, PhD | Director | 18 Jun 2026 | 14,950 | 14,950 | - | - | Stock options (right to buy) | ||
| Ms. Cecilia Jones | Chief Financial Officer | 18 Jun 2026 | 3,000 | 9,000 | - | - | Performance share units | ||
| Ms. Cecilia Jones | Chief Financial Officer | 18 Jun 2026 | 3,000 | 3,000 | - | - | Restricted stock units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 18 Jun 2026 | 3,000 | 9,000 | - | - | Performance share units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 18 Jun 2026 | 3,000 | 3,000 | - | - | Restricted stock units | ||
| Dr. Krishnan Viswanadhan | Chief Strategy and Operations | 18 Jun 2026 | 3,000 | 3,000 | - | - | Restricted stock units | ||
| Dr. Krishnan Viswanadhan | Chief Strategy and Operations | 18 Jun 2026 | 3,000 | 9,000 | - | - | Performance share units | ||
| Mr. James William Burns | Chief Legal Officer | 18 Jun 2026 | 3,000 | 9,000 | - | - | Performance share units | ||
| Mr. James William Burns | Chief Legal Officer | 18 Jun 2026 | 3,000 | 3,000 | - | - | Restricted stock units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | 18 Jun 2026 | 3,000 | 3,000 | - | - | Restricted stock units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | 18 Jun 2026 | 3,000 | 9,000 | - | - | Performance share units | ||
| Mr. Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2026 | 1,976 | 8,049 (0%) | 0% | 0 | Common stock | |
| Mr. Jeffrey D. Capello | Director | 13 Jun 2026 | 1,976 | 0 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | 02 Apr 2026 | 13,500 | 40,500 | - | - | Performance share units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2026 | 25,528 | 190,076 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.71 per share. | 02 Apr 2026 | 12,472 | 177,604 (0%) | 0% | 34.7 | 432,903 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2026 | 13,500 | 191,104 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.71 per share. | 02 Apr 2026 | 6,596 | 184,508 (0%) | 0% | 34.7 | 228,947 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | 02 Apr 2026 | 25,528 | 0 | - | - | Performance share units | ||
| Ms. Cecilia Jones | Chief Financial Officer | 02 Apr 2026 | 8,500 | 8,500 | - | - | Performance share units | ||
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2026 | 8,500 | 58,139 (0%) | 0% | 0 | Common stock | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.71 per share. | 02 Apr 2026 | 3,141 | 54,998 (0%) | 0% | 34.7 | 109,024 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2026 | 8,500 | 83,217 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 02 Apr 2026 | 8,500 | 8,500 | - | - | Performance share units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.71 per share. | 02 Apr 2026 | 2,940 | 80,277 (0%) | 0% | 34.7 | 102,047 | Common stock |
| Dr. Krishnan Viswanadhan | Chief Corp Dev & Strategy | 02 Apr 2026 | 8,100 | 8,100 | - | - | Performance share units | ||
| Dr. Krishnan Viswanadhan | Chief Corp Dev & Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2026 | 8,100 | 13,241 (0%) | 0% | 0 | Common stock | |
| Dr. Krishnan Viswanadhan | Chief Corp Dev & Strategy | Sale of securities on an exchange or to another person at price $ 34.71 per share. | 02 Apr 2026 | 2,959 | 10,282 (0%) | 0% | 34.7 | 102,707 | Common stock |
| Mr. James William Burns | Chief Legal Officer | 02 Apr 2026 | 8,500 | 8,500 | - | - | Performance share units | ||
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 34.71 per share. | 02 Apr 2026 | 3,280 | 49,306 (0%) | 0% | 34.7 | 113,849 | Common stock |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2026 | 8,500 | 52,586 (0%) | 0% | 0 | Common stock | |
| Ms. Tsveta Milanova | Chief Commercial Officer | 02 Apr 2026 | 8,500 | 8,500 | - | - | Performance share units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 34.71 per share. | 02 Apr 2026 | 3,262 | 46,829 (0%) | 0% | 34.7 | 113,224 | Common stock |
| Ms. Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2026 | 8,500 | 50,091 (0%) | 0% | 0 | Common stock | |
| Dr. Krishnan Viswanadhan | Chief Corp Dev & Strategy | 05 Mar 2026 | 8,100 | 16,200 | - | - | Restricted stock units | ||
| Dr. Krishnan Viswanadhan | Chief Corp Dev & Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2026 | 8,100 | 8,100 (0%) | 0% | 0 | Common stock | |
| Dr. Krishnan Viswanadhan | Chief Corp Dev & Strategy | Sale of securities on an exchange or to another person at price $ 27.80 per share. | 05 Mar 2026 | 2,959 | 5,141 (0%) | 0% | 27.8 | 82,260 | Common stock |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.88 per share. | 03 Mar 2026 | 5,272 | 868 (0%) | 0% | 28.9 | 152,255 | Common stock |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.88 per share. | 03 Mar 2026 | 5,272 | 868 (0%) | 0% | 28.9 | 152,255 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 8,500 | 151,603 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | 01 Mar 2026 | 13,000 | 26,000 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | 01 Mar 2026 | 18,000 | 18,000 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | 01 Mar 2026 | 8,500 | 0 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | 01 Mar 2026 | 174,000 | 174,000 | - | - | Stock options (right to buy) | ||
| Mr. Brian Goff | Director, Chief Executive Officer | 01 Mar 2026 | 48,000 | 48,000 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 5,918 | 164,548 (0%) | 0% | 29.0 | 171,385 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 13,000 | 170,466 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 8,267 | 157,466 (0%) | 0% | 29.0 | 239,412 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 18,000 | 165,733 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 3,870 | 147,733 (0%) | 0% | 29.0 | 112,075 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2026 | 14,000 | 14,000 | - | - | Restricted stock units | ||
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2026 | 52,000 | 52,000 | - | - | Stock options (right to buy) | ||
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2026 | 2,000 | 0 | - | - | Restricted stock units | ||
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2026 | 5,666 | 5,667 | - | - | Restricted stock units | ||
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2026 | 4,000 | 8,000 | - | - | Restricted stock units | ||
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2026 | 5,303 | 10,607 | - | - | Restricted stock units | ||
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 2,000 | 39,394 (0%) | 0% | 0 | Common stock | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 594 | 38,800 (0%) | 0% | 29.0 | 17,202 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 5,666 | 44,466 (0%) | 0% | 0 | Common stock | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,681 | 42,785 (0%) | 0% | 29.0 | 48,682 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 46,785 (0%) | 0% | 0 | Common stock | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 45,598 (0%) | 0% | 29.0 | 34,376 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 5,303 | 50,901 (0%) | 0% | 0 | Common stock | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,573 | 49,328 (0%) | 0% | 29.0 | 45,554 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2026 | 4,000 | 8,000 | - | - | Restricted stock units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 68,795 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 67,608 (0%) | 0% | 29.0 | 34,376 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 5,666 | 73,274 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,681 | 71,593 (0%) | 0% | 29.0 | 48,682 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 75,593 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 74,406 (0%) | 0% | 29.0 | 34,376 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2026 | 14,000 | 14,000 | - | - | Restricted stock units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2026 | 22,000 | 22,000 | - | - | Restricted stock units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2026 | 52,000 | 52,000 | - | - | Stock options (right to buy) | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2026 | 4,000 | 0 | - | - | Restricted stock units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2026 | 5,666 | 5,667 | - | - | Restricted stock units | ||
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 2,350 | 3,293 (0%) | 0% | 0 | Common stock | |
| Mr. T. J. Washburn | Principal Accounting Officer | 01 Mar 2026 | 2,695 | 5,390 | - | - | Restricted stock units | ||
| Mr. T. J. Washburn | Principal Accounting Officer | 01 Mar 2026 | 2,450 | 2,450 | - | - | Restricted stock units | ||
| Mr. T. J. Washburn | Principal Accounting Officer | 01 Mar 2026 | 2,350 | 0 | - | - | Restricted stock units | ||
| Mr. T. J. Washburn | Principal Accounting Officer | 01 Mar 2026 | 8,452 | 8,452 | - | - | Restricted stock units | ||
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 798 | 6,140 (0%) | 0% | 29.0 | 23,110 | Common stock |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 2,695 | 6,938 (0%) | 0% | 0 | Common stock | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 727 | 4,243 (0%) | 0% | 29.0 | 21,054 | Common stock |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 2,450 | 4,970 (0%) | 0% | 0 | Common stock | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 698 | 2,595 (0%) | 0% | 29.0 | 20,214 | Common stock |
| Dr. Krishnan Viswanadhan | Chief Corp Dev & Strategy | 01 Mar 2026 | 14,000 | 14,000 | - | - | Restricted stock units | ||
| Dr. Krishnan Viswanadhan | Chief Corp Dev & Strategy | 01 Mar 2026 | 52,000 | 52,000 | - | - | Stock options (right to buy) | ||
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 35,718 (0%) | 0% | 0 | Common stock | |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 5,666 | 40,197 (0%) | 0% | 0 | Common stock | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,681 | 38,516 (0%) | 0% | 29.0 | 48,682 | Common stock |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 42,516 (0%) | 0% | 0 | Common stock | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 41,329 (0%) | 0% | 29.0 | 34,376 | Common stock |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 3,920 | 45,249 (0%) | 0% | 0 | Common stock | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,163 | 44,086 (0%) | 0% | 29.0 | 33,680 | Common stock |
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2026 | 14,000 | 14,000 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2026 | 52,000 | 52,000 | - | - | Stock options (right to buy) | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2026 | 4,000 | 0 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2026 | 5,666 | 5,667 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2026 | 4,000 | 8,000 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2026 | 3,920 | 7,839 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 34,531 (0%) | 0% | 29.0 | 34,376 | Common stock |
| Ms. Tsveta Milanova | Chief Commercial Officer | 01 Mar 2026 | 4,000 | 8,000 | - | - | Restricted stock units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | 01 Mar 2026 | 14,000 | 14,000 | - | - | Restricted stock units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | 01 Mar 2026 | 52,000 | 52,000 | - | - | Stock options (right to buy) | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | 01 Mar 2026 | 5,666 | 5,667 | - | - | Restricted stock units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 5,666 | 40,459 (0%) | 0% | 0 | Common stock | |
| Ms. Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,681 | 38,778 (0%) | 0% | 29.0 | 48,682 | Common stock |
| Ms. Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 42,778 (0%) | 0% | 0 | Common stock | |
| Ms. Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 41,591 (0%) | 0% | 29.0 | 34,376 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 2,000 | 39,394 (0%) | 0% | 0 | - | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 594 | 38,800 (0%) | 0% | 29.0 | 17,202 | - |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 5,666 | 44,466 (0%) | 0% | 0 | - | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,681 | 42,785 (0%) | 0% | 29.0 | 48,682 | - |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 46,785 (0%) | 0% | 0 | - | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 45,598 (0%) | 0% | 29.0 | 34,376 | - |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 5,303 | 50,901 (0%) | 0% | 0 | - | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,573 | 49,328 (0%) | 0% | 29.0 | 45,554 | - |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 2,350 | 3,293 (0%) | 0% | 0 | - | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 698 | 2,595 (0%) | 0% | 29.0 | 20,214 | - |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 2,450 | 4,970 (0%) | 0% | 0 | - | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 727 | 4,243 (0%) | 0% | 29.0 | 21,054 | - |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 2,695 | 6,938 (0%) | 0% | 0 | - | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 798 | 6,140 (0%) | 0% | 29.0 | 23,110 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 8,500 | 151,603 (0%) | 0% | 0 | - | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 3,870 | 147,733 (0%) | 0% | 29.0 | 112,075 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 18,000 | 165,733 (0%) | 0% | 0 | - | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 8,267 | 157,466 (0%) | 0% | 29.0 | 239,412 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 13,000 | 170,466 (0%) | 0% | 0 | - | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 5,918 | 164,548 (0%) | 0% | 29.0 | 171,385 | - |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 35,718 (0%) | 0% | 0 | - | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 34,531 (0%) | 0% | 29.0 | 34,376 | - |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 5,666 | 40,197 (0%) | 0% | 0 | - | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,681 | 38,516 (0%) | 0% | 29.0 | 48,682 | - |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 42,516 (0%) | 0% | 0 | - | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 41,329 (0%) | 0% | 29.0 | 34,376 | - |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 3,920 | 45,249 (0%) | 0% | 0 | - | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,163 | 44,086 (0%) | 0% | 29.0 | 33,680 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 68,795 (0%) | 0% | 0 | - | |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 67,608 (0%) | 0% | 29.0 | 34,376 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 5,666 | 73,274 (0%) | 0% | 0 | - | |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,681 | 71,593 (0%) | 0% | 29.0 | 48,682 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2026 | 4,000 | 75,593 (0%) | 0% | 0 | - | |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 01 Mar 2026 | 1,187 | 74,406 (0%) | 0% | 29.0 | 34,376 | - |
| Ms. Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 8,475 | 37,665 (0%) | 0% | 0 | Common stock | |
| Ms. Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 27.02 per share. | 05 Jan 2026 | 2,872 | 34,793 (0%) | 0% | 27.0 | 77,601 | Common stock |
| Ms. Tsveta Milanova | Chief Commercial Officer | 05 Jan 2026 | 8,475 | 0 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 6,000 | 34,650 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | 30 Dec 2025 | 25,528 | 25,528 | - | - | Performance share units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 6,000 | 67,727 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 2,932 | 64,795 (0%) | 0% | 27.1 | 79,428 | Common stock |
| Ms. Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 2,932 | 29,190 (0%) | 0% | 27.1 | 79,428 | Common stock |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 2,932 | 31,718 (0%) | 0% | 27.1 | 79,428 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 6,230 | 143,103 (0%) | 0% | 27.1 | 168,771 | Common stock |
| Ms. Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 6,000 | 32,122 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 12,750 | 149,333 (0%) | 0% | 0 | Common stock | |
| Mr. James William Burns | Chief Legal Officer | 30 Dec 2025 | 6,000 | 0 | - | - | Performance share units | ||
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 6,000 | 40,326 (0%) | 0% | 0 | Common stock | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 2,932 | 37,394 (0%) | 0% | 27.1 | 79,428 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 12,473 | 136,583 (0%) | 0% | 27.1 | 337,894 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 25,528 | 149,056 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | 30 Dec 2025 | 12,750 | 0 | - | - | Performance share units | ||
| Ms. Cecilia Jones | Chief Financial Officer | 30 Dec 2025 | 6,000 | 0 | - | - | Performance share units | ||
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 6,000 | 67,727 (0%) | 0% | 0 | - | |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 2,932 | 64,795 (0%) | 0% | 27.1 | 79,428 | - |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 6,000 | 40,326 (0%) | 0% | 0 | - | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 2,932 | 37,394 (0%) | 0% | 27.1 | 79,428 | - |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 6,000 | 34,650 (0%) | 0% | 0 | - | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 2,932 | 31,718 (0%) | 0% | 27.1 | 79,428 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 25,528 | 149,056 (0%) | 0% | 0 | - | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 12,473 | 136,583 (0%) | 0% | 27.1 | 337,894 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2025 | 12,750 | 149,333 (0%) | 0% | 0 | - | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 30 Dec 2025 | 6,230 | 143,103 (0%) | 0% | 27.1 | 168,771 | - |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 30 Dec 2025 | 6,000 | 0 | - | - | Performance share units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | 30 Dec 2025 | 6,000 | 0 | - | - | Performance share units | ||
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 43.84 per share. | 12 Nov 2025 | 200 | 17,603 (0%) | 0% | 43.8 | 8,768 | Common stock |
| Dr. David T. Scadden, M.D. | Director | 12 Nov 2025 | 200 | 26,907 | - | - | Stock options (right to buy) | ||
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 12 Nov 2025 | 200 | 17,803 (0%) | 0% | 18.1 | 3,618 | Common stock |
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 12 Nov 2025 | 200 | 17,803 (0%) | 0% | 18.1 | 3,618 | - |
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 43.84 per share. | 12 Nov 2025 | 200 | 17,603 (0%) | 0% | 43.8 | 8,768 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. | 11 Nov 2025 | 2,454 | 64,181 (0%) | 0% | 25.0 | 61,375 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.78 per share. | 11 Nov 2025 | 2,454 | 61,727 (0%) | 0% | 43.8 | 107,436 | - |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 11 Nov 2025 | 2,454 | 26,130 | - | - | Stock options (right to buy) | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.78 per share. | 11 Nov 2025 | 2,454 | 61,727 (0%) | 0% | 43.8 | 107,436 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. | 11 Nov 2025 | 2,454 | 64,181 (0%) | 0% | 25.0 | 61,375 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 30 Oct 2025 | 200 | 28,584 | - | - | Stock options (right to buy) | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.81 per share. | 30 Oct 2025 | 200 | 61,727 (0%) | 0% | 43.8 | 8,762 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. | 30 Oct 2025 | 200 | 61,927 (0%) | 0% | 25.0 | 5,002 | Common stock |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. | 30 Oct 2025 | 200 | 61,927 (0%) | 0% | 25.0 | 5,002 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.81 per share. | 30 Oct 2025 | 200 | 61,727 (0%) | 0% | 43.8 | 8,762 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. | 27 Oct 2025 | 3,302 | 65,029 (0%) | 0% | 25.0 | 82,583 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.92 per share. | 27 Oct 2025 | 3,302 | 61,727 (0%) | 0% | 43.9 | 145,024 | - |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 27 Oct 2025 | 3,302 | 28,784 | - | - | Stock options (right to buy) | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.92 per share. | 27 Oct 2025 | 3,302 | 61,727 (0%) | 0% | 43.9 | 145,024 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. | 27 Oct 2025 | 3,302 | 65,029 (0%) | 0% | 25.0 | 82,583 | Common stock |
| Dr. David T. Scadden, M.D. | Director | 08 Oct 2025 | 200 | 27,107 | - | - | Stock options (right to buy) | ||
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 41.00 per share. | 08 Oct 2025 | 200 | 17,603 (0%) | 0% | 41 | 8,200 | Common stock |
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 08 Oct 2025 | 200 | 17,803 (0%) | 0% | 18.1 | 3,618 | Common stock |
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 08 Oct 2025 | 200 | 17,803 (0%) | 0% | 18.1 | 3,618 | - |
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 41.00 per share. | 08 Oct 2025 | 200 | 17,603 (0%) | 0% | 41 | 8,200 | - |
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 30 Sep 2025 | 200 | 17,803 (0%) | 0% | 18.1 | 3,618 | - |
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 30 Sep 2025 | 200 | 17,603 (0%) | 0% | 40 | 8,000 | - |
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 30 Sep 2025 | 200 | 17,803 (0%) | 0% | 18.1 | 3,618 | Common stock |
| Dr. David T. Scadden, M.D. | Director | 30 Sep 2025 | 200 | 27,307 | - | - | Stock options (right to buy) | ||
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 30 Sep 2025 | 200 | 17,603 (0%) | 0% | 40 | 8,000 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2025 | 7,472 | 37,521 (0%) | 0% | 0 | Common stock | |
| Ms. Cecilia Jones | Chief Financial Officer | 26 Sep 2025 | 7,472 | 0 | - | - | Restricted stock units | ||
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.77 per share. | 26 Sep 2025 | 3,651 | 33,870 (0%) | 0% | 36.8 | 134,247 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2025 | 7,472 | 37,521 (0%) | 0% | 0 | - | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.77 per share. | 26 Sep 2025 | 3,651 | 33,870 (0%) | 0% | 36.8 | 134,247 | - |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 36.87 per share. | 05 Sep 2025 | 8,546 | 868 (0%) | 0% | 36.9 | 315,091 | - |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 36.87 per share. | 05 Sep 2025 | 8,546 | 868 (0%) | 0% | 36.9 | 315,091 | Common stock |
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 27 Aug 2025 | 200 | 17,803 (0%) | 0% | 18.1 | 3,618 | Common stock |
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 27 Aug 2025 | 200 | 17,603 (0%) | 0% | 40 | 8,000 | Common stock |
| Dr. David T. Scadden, M.D. | Director | 27 Aug 2025 | 200 | 27,507 | - | - | Stock options (right to buy) | ||
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 27 Aug 2025 | 200 | 17,803 (0%) | 0% | 18.1 | 3,618 | - |
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 27 Aug 2025 | 200 | 17,603 (0%) | 0% | 40 | 8,000 | - |
| Dr. Rahul D. Ballal, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 2,302 | 12,414 (0%) | 0% | 0 | - | |
| Ms. Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 2,302 | 12,414 (0%) | 0% | 0 | - | |
| Ms. Cynthia Smith | Director | 11 Aug 2025 | 2,302 | 0 | - | - | Restricted stock units | ||
| Ms. Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 2,302 | 12,414 (0%) | 0% | 0 | Common stock | |
| Dr. Rahul D. Ballal, PhD | Director | 11 Aug 2025 | 2,302 | 0 | - | - | Restricted stock units | ||
| Dr. Rahul D. Ballal, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 2,302 | 12,414 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | 08 Aug 2025 | 22,691 | 0 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.67 per share. | 08 Aug 2025 | 11,085 | 123,528 (0%) | 0% | 36.7 | 406,487 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2025 | 22,691 | 134,613 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2025 | 22,691 | 134,613 (0%) | 0% | 0 | - | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.67 per share. | 08 Aug 2025 | 11,085 | 123,528 (0%) | 0% | 36.7 | 406,487 | - |
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 10 Jul 2025 | 1,400 | 19,003 (0%) | 0% | 18.1 | 25,326 | - |
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 10 Jul 2025 | 1,400 | 17,603 (0%) | 0% | 40 | 56,000 | - |
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 10 Jul 2025 | 1,400 | 19,003 (0%) | 0% | 18.1 | 25,326 | Common stock |
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 10 Jul 2025 | 1,400 | 17,603 (0%) | 0% | 40 | 56,000 | Common stock |
| Dr. David T. Scadden, M.D. | Director | 10 Jul 2025 | 1,400 | 27,707 | - | - | Stock options (right to buy) | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 09 Jul 2025 | 11,914 | 32,086 | - | - | Stock options (right to buy) | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.76 per share. | 09 Jul 2025 | 847 | 61,271 (0%) | 0% | 38.8 | 32,830 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.93 per share. | 09 Jul 2025 | 11,067 | 62,118 (0%) | 0% | 37.9 | 419,771 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. | 09 Jul 2025 | 11,914 | 73,185 (0%) | 0% | 25.0 | 297,969 | Common stock |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. | 09 Jul 2025 | 11,914 | 73,185 (0%) | 0% | 25.0 | 297,969 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.93 per share. | 09 Jul 2025 | 11,067 | 62,118 (0%) | 0% | 37.9 | 419,771 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.76 per share. | 09 Jul 2025 | 847 | 61,271 (0%) | 0% | 38.8 | 32,830 | - |
| Dr. Jay T. Backstrom, M.D.,M.P.H. | Director | 08 Jul 2025 | 23,393 | 23,393 | - | - | Stock options (right to buy) | ||
| Dr. Jay T. Backstrom, M.D.,M.P.H. | Director | 08 Jul 2025 | 4,341 | 4,341 | - | - | Restricted stock units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2025 | 8,374 | 65,362 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Jul 2025 | 8,374 | 8,375 | - | - | Restricted stock units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.17 per share. | 01 Jul 2025 | 4,091 | 61,271 (0%) | 0% | 34.2 | 139,789 | Common stock |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2025 | 8,374 | 65,362 (0%) | 0% | 0 | - | |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.17 per share. | 01 Jul 2025 | 4,091 | 61,271 (0%) | 0% | 34.2 | 139,789 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 25,527 | 117,872 (0%) | 0% | 0 | - | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 12,471 | 105,401 (0%) | 0% | 33.5 | 418,277 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 12,750 | 118,151 (0%) | 0% | 0 | - | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 6,229 | 111,922 (0%) | 0% | 33.5 | 208,921 | - |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 31,829 (0%) | 0% | 0 | - | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 1,780 | 30,049 (0%) | 0% | 33.5 | 59,701 | - |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 31,449 (0%) | 0% | 0 | - | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 2,799 | 28,650 (0%) | 0% | 33.5 | 93,878 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 59,897 (0%) | 0% | 0 | - | |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 2,909 | 56,988 (0%) | 0% | 33.5 | 97,568 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | 24 Jun 2025 | 12,750 | 12,750 | - | - | Performance share units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 25,527 | 117,872 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 12,471 | 105,401 (0%) | 0% | 33.5 | 418,277 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 12,750 | 118,151 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 6,229 | 111,922 (0%) | 0% | 33.5 | 208,921 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | 24 Jun 2025 | 25,527 | 51,056 | - | - | Performance share units | ||
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 31,829 (0%) | 0% | 0 | Common stock | |
| Ms. Cecilia Jones | Chief Financial Officer | 24 Jun 2025 | 6,000 | 6,000 | - | - | Performance share units | ||
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 1,780 | 30,049 (0%) | 0% | 33.5 | 59,701 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 2,909 | 56,988 (0%) | 0% | 33.5 | 97,568 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 59,897 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 24 Jun 2025 | 6,000 | 6,000 | - | - | Performance share units | ||
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 2,799 | 28,650 (0%) | 0% | 33.5 | 93,878 | Common stock |
| Mr. James William Burns | Chief Legal Officer | 24 Jun 2025 | 6,000 | 6,000 | - | - | Performance share units | ||
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 31,449 (0%) | 0% | 0 | Common stock | |
| Ms. Tsveta Milanova | Chief Commercial Officer | 24 Jun 2025 | 6,000 | 6,000 | - | - | Performance share units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2025 | 6,000 | 28,892 (0%) | 0% | 0 | Common stock | |
| Ms. Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 24 Jun 2025 | 2,770 | 26,122 (0%) | 0% | 33.5 | 92,906 | Common stock |
| Mr. Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 6,073 (0%) | 0% | 0 | Common stock | |
| Mr. Jeffrey D. Capello | Director | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | ||
| Mr. Jeffrey D. Capello | Director | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | ||
| Mr. Jeffrey D. Capello | Director | 18 Jun 2025 | 2,861 | 2,861 | - | - | Restricted stock units | ||
| Ms. Kaye Foster | Director | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | ||
| Ms. Kaye Foster | Director | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | ||
| Ms. Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 7,468 (0%) | 0% | 0 | Common stock | |
| Ms. Kaye Foster | Director | 18 Jun 2025 | 2,816 | 2,816 | - | - | Restricted stock units | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | 18 Jun 2025 | 2,816 | 2,816 | - | - | Restricted stock units | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 151,340 (0%) | 0% | 0 | Common stock | |
| Ms. Cynthia Smith | Director | 18 Jun 2025 | 2,816 | 2,816 | - | - | Restricted stock units | ||
| Ms. Cynthia Smith | Director | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | ||
| Ms. Cynthia Smith | Director | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | ||
| Ms. Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 10,112 (0%) | 0% | 0 | Common stock | |
| Dr. Maykin Ho, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 17,032 (0%) | 0% | 0 | Common stock | |
| Dr. Maykin Ho, PhD | Director | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | ||
| Dr. Maykin Ho, PhD | Director | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | ||
| Dr. Maykin Ho, PhD | Director | 18 Jun 2025 | 2,816 | 2,816 | - | - | Restricted stock units | ||
| Dr. David T. Scadden, M.D. | Director | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | ||
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 17,603 (0%) | 0% | 0 | Common stock | |
| Dr. David T. Scadden, M.D. | Director | 18 Jun 2025 | 2,816 | 2,816 | - | - | Restricted stock units | ||
| Dr. David T. Scadden, M.D. | Director | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | ||
| Dr. Rahul D. Ballal, PhD | Director | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | ||
| Dr. Rahul D. Ballal, PhD | Director | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | ||
| Dr. Rahul D. Ballal, PhD | Director | 18 Jun 2025 | 2,816 | 2,816 | - | - | Restricted stock units | ||
| Dr. Rahul D. Ballal, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 10,112 (0%) | 0% | 0 | Common stock | |
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 17,603 (0%) | 0% | 0 | - | |
| Ms. Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 10,112 (0%) | 0% | 0 | - | |
| Dr. Maykin Ho, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 17,032 (0%) | 0% | 0 | - | |
| Ms. Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 7,468 (0%) | 0% | 0 | - | |
| Dr. Jacqualyn A. Fouse, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 151,340 (0%) | 0% | 0 | - | |
| Dr. Rahul D. Ballal, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 10,112 (0%) | 0% | 0 | - | |
| Mr. Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 6,073 (0%) | 0% | 0 | - | |
| Mr. Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2025 | 1,977 | 3,953 (0%) | 0% | 0 | - | |
| Mr. Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2025 | 1,977 | 3,953 (0%) | 0% | 0 | Common stock | |
| Mr. Jeffrey D. Capello | Director | 13 Jun 2025 | 1,977 | 1,976 | - | - | Restricted stock units | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2025 | 15,933 | 156,717 (0%) | 0% | 0 | Common stock | |
| Dr. Jacqualyn A. Fouse, PhD | Director | 08 Apr 2025 | 15,933 | 0 | - | - | Restricted stock units | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | Sale of securities on an exchange or to another person at price $ 25.90 per share. | 08 Apr 2025 | 7,497 | 149,220 (0%) | 0% | 25.9 | 194,172 | Common stock |
| Dr. Jacqualyn A. Fouse, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2025 | 15,933 | 156,717 (0%) | 0% | 0 | - | |
| Dr. Jacqualyn A. Fouse, PhD | Director | Sale of securities on an exchange or to another person at price $ 25.90 per share. | 08 Apr 2025 | 7,497 | 149,220 (0%) | 0% | 25.9 | 194,172 | - |
| Dr. Krishnan Viswanadhan | Chief Corp Dev & Strategy | 05 Mar 2025 | 55,374 | 55,374 | - | - | Stock options (right to buy) | ||
| Dr. Krishnan Viswanadhan | Chief Corp Dev & Strategy | 05 Mar 2025 | 24,300 | 24,300 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 8,500 | 87,292 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | 01 Mar 2025 | 18,000 | 36,000 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | 01 Mar 2025 | 8,500 | 8,500 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | 01 Mar 2025 | 142,500 | 142,500 | - | - | Stock options (right to buy) | ||
| Mr. Brian Goff | Director, Chief Executive Officer | 01 Mar 2025 | 39,000 | 39,000 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 8,794 | 92,345 (0%) | 0% | 35.5 | 312,539 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 18,000 | 101,139 (0%) | 0% | 0 | Common stock | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 4,153 | 83,139 (0%) | 0% | 35.5 | 147,598 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 594 | 21,843 (0%) | 0% | 35.5 | 21,111 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,000 | 22,437 (0%) | 0% | 0 | Common stock | |
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | ||
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2025 | 2,000 | 2,000 | - | - | Restricted stock units | ||
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | ||
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2025 | 15,910 | 15,910 | - | - | Restricted stock units | ||
| Ms. Cecilia Jones | Chief Financial Officer | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | ||
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 25,829 (0%) | 0% | 35.5 | 59,743 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 27,510 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2025 | 4,000 | 4,000 | - | - | Restricted stock units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 48,235 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,137 | 47,098 (0%) | 0% | 35.5 | 40,409 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 51,098 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,187 | 49,911 (0%) | 0% | 35.5 | 42,186 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 55,578 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 53,897 (0%) | 0% | 35.5 | 59,743 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2025 | 3,833 | 0 | - | - | Restricted stock units | ||
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | ||
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 727 | 9,414 (0%) | 0% | 35.5 | 25,838 | Common stock |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 697 | 7,691 (0%) | 0% | 35.5 | 24,771 | Common stock |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 777 | 6,269 (0%) | 0% | 0 | Common stock | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 231 | 6,038 (0%) | 0% | 35.5 | 8,210 | Common stock |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,350 | 8,388 (0%) | 0% | 0 | Common stock | |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,450 | 10,141 (0%) | 0% | 0 | Common stock | |
| Mr. T. J. Washburn | Principal Accounting Officer | 01 Mar 2025 | 2,450 | 4,900 | - | - | Restricted stock units | ||
| Mr. T. J. Washburn | Principal Accounting Officer | 01 Mar 2025 | 2,350 | 2,350 | - | - | Restricted stock units | ||
| Mr. T. J. Washburn | Principal Accounting Officer | 01 Mar 2025 | 777 | 0 | - | - | Restricted stock units | ||
| Mr. T. J. Washburn | Principal Accounting Officer | 01 Mar 2025 | 6,142 | 6,142 | - | - | Restricted stock units | ||
| Mr. T. J. Washburn | Principal Accounting Officer | 01 Mar 2025 | 8,085 | 8,085 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2025 | 11,759 | 11,759 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2025 | 3,833 | 0 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | 01 Mar 2025 | 4,000 | 4,000 | - | - | Restricted stock units | ||
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 19,787 (0%) | 0% | 0 | Common stock | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,137 | 18,650 (0%) | 0% | 35.5 | 40,409 | Common stock |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 22,650 (0%) | 0% | 0 | Common stock | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,187 | 21,463 (0%) | 0% | 35.5 | 42,186 | Common stock |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 27,130 (0%) | 0% | 0 | Common stock | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 25,449 (0%) | 0% | 35.5 | 59,743 | Common stock |
| Ms. Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 24,573 (0%) | 0% | 0 | Common stock | |
| Ms. Tsveta Milanova | Chief Commercial Officer | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 22,892 (0%) | 0% | 35.5 | 59,743 | Common stock |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 777 | 6,269 (0%) | 0% | 0 | - | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 231 | 6,038 (0%) | 0% | 35.5 | 8,210 | - |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,350 | 8,388 (0%) | 0% | 0 | - | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 697 | 7,691 (0%) | 0% | 35.5 | 24,771 | - |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,450 | 10,141 (0%) | 0% | 0 | - | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 727 | 9,414 (0%) | 0% | 35.5 | 25,838 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 48,235 (0%) | 0% | 0 | - | |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,137 | 47,098 (0%) | 0% | 35.5 | 40,409 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 51,098 (0%) | 0% | 0 | - | |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,187 | 49,911 (0%) | 0% | 35.5 | 42,186 | - |
| Ms. Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 55,578 (0%) | 0% | 0 | - | |
| Ms. Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 53,897 (0%) | 0% | 35.5 | 59,743 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 8,500 | 87,292 (0%) | 0% | 0 | - | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 4,153 | 83,139 (0%) | 0% | 35.5 | 147,598 | - |
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 18,000 | 101,139 (0%) | 0% | 0 | - | |
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 8,794 | 92,345 (0%) | 0% | 35.5 | 312,539 | - |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 19,787 (0%) | 0% | 0 | - | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,137 | 18,650 (0%) | 0% | 35.5 | 40,409 | - |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 22,650 (0%) | 0% | 0 | - | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,187 | 21,463 (0%) | 0% | 35.5 | 42,186 | - |
| Mr. James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 27,130 (0%) | 0% | 0 | - | |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 25,449 (0%) | 0% | 35.5 | 59,743 | - |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,000 | 22,437 (0%) | 0% | 0 | - | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 594 | 21,843 (0%) | 0% | 35.5 | 21,111 | - |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 27,510 (0%) | 0% | 0 | - | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 25,829 (0%) | 0% | 35.5 | 59,743 | - |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 6,896 | 7,709 (0%) | 0% | 0 | - | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 34.39 per share. | 01 Feb 2025 | 2,272 | 5,437 (0%) | 0% | 34.4 | 78,134 | - |
| Mr. T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 6,896 | 7,709 (0%) | 0% | 0 | Common stock | |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 34.39 per share. | 01 Feb 2025 | 2,272 | 5,437 (0%) | 0% | 34.4 | 78,134 | Common stock |
| Mr. T. J. Washburn | Principal Accounting Officer | 01 Feb 2025 | 6,896 | 0 | - | - | Restricted stock units | ||
| Ms. Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 8,476 | 21,710 (0%) | 0% | 0 | Common stock | |
| Ms. Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 32.18 per share. | 03 Jan 2025 | 2,804 | 18,906 (0%) | 0% | 32.2 | 90,233 | Common stock |
| Ms. Tsveta Milanova | Chief Commercial Officer | 03 Jan 2025 | 8,476 | 8,475 | - | - | Restricted stock units | ||
| Dr. David T. Scadden, M.D. | Director | Sale of securities on an exchange or to another person at price $ 46.28 per share. | 11 Dec 2024 | 200 | 15,483 (0%) | 0% | 46.3 | 9,256 | Common stock |
| Dr. David T. Scadden, M.D. | Director | 11 Dec 2024 | 200 | 29,107 | - | - | Stock options (right to buy) | ||
| Dr. David T. Scadden, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 11 Dec 2024 | 200 | 15,683 (0%) | 0% | 18.1 | 3,618 | Common stock |
| Mr. T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 56.09 per share. | 08 Nov 2024 | 772 | 813 (0%) | 0% | 56.1 | 43,301 | Common stock |
| Dr. Rahul D. Ballal, PhD | Director | Sale of securities on an exchange or to another person at price $ 53.32 per share. | 07 Nov 2024 | 8,132 | 9,860 (0%) | 0% | 53.3 | 433,598 | Common stock |
| Dr. Rahul D. Ballal, PhD | Director | 07 Nov 2024 | 10,000 | 27,947 | - | - | Stock option (right to buy) | ||
| Dr. Rahul D. Ballal, PhD | Director | 07 Nov 2024 | 10,000 | 17,947 | - | - | Stock option (right to buy) | ||
| Dr. Rahul D. Ballal, PhD | Director | Sale of securities on an exchange or to another person at price $ 54.41 per share. | 07 Nov 2024 | 1,868 | 7,992 (0%) | 0% | 54.4 | 101,638 | Common stock |
| Dr. Rahul D. Ballal, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.99 per share. | 07 Nov 2024 | 10,000 | 17,992 (0%) | 0% | 26.0 | 259,900 | Common stock |
| Dr. Rahul D. Ballal, PhD | Director | Sale of securities on an exchange or to another person at price $ 59.21 per share. | 07 Nov 2024 | 1,500 | 7,992 (0%) | 0% | 59.2 | 88,815 | Common stock |
| Dr. Rahul D. Ballal, PhD | Director | Sale of securities on an exchange or to another person at price $ 58.57 per share. | 07 Nov 2024 | 4,929 | 9,492 (0%) | 0% | 58.6 | 288,692 | Common stock |
| Dr. Rahul D. Ballal, PhD | Director | Sale of securities on an exchange or to another person at price $ 57.24 per share. | 07 Nov 2024 | 3,571 | 14,421 (0%) | 0% | 57.2 | 204,404 | Common stock |
| Dr. Rahul D. Ballal, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.99 per share. | 07 Nov 2024 | 10,000 | 17,992 (0%) | 0% | 26.0 | 259,900 | Common stock |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 52.00 per share. | 07 Nov 2024 | 13,411 | 24,041 (0%) | 0% | 52 | 697,372 | Common stock |
| Mr. James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 52.56 per share. | 07 Nov 2024 | 8,341 | 15,700 (0%) | 0% | 52.6 | 438,403 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2024 | 7,473 | 22,700 (0%) | 0% | 0 | Common stock | |
| Ms. Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.03 per share. | 26 Sep 2024 | 2,542 | 20,158 (0%) | 0% | 49.0 | 124,634 | Common stock |
| Ms. Cecilia Jones | Chief Financial Officer | 26 Sep 2024 | 7,473 | 7,472 | - | - | Restricted stock units | ||
| Ms. Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 7,992 (0%) | 0% | 0 | Common stock | |
| Ms. Cynthia Smith | Director | 11 Aug 2024 | 2,302 | 2,302 | - | - | Restricted stock units | ||
| Dr. Rahul D. Ballal, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 7,992 (0%) | 0% | 0 | Common stock | |
| Dr. Rahul D. Ballal, PhD | Director | 11 Aug 2024 | 2,302 | 2,302 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.75 per share. | 08 Aug 2024 | 11,091 | 78,792 (0%) | 0% | 42.7 | 474,140 | Common stock |
| Mr. Brian Goff | Director, Chief Executive Officer | 08 Aug 2024 | 22,691 | 22,691 | - | - | Restricted stock units | ||
| Mr. Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 22,691 | 89,883 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 8,375 | 47,441 (0%) | 0% | 0 | Common stock | |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.85 per share. | 01 Jul 2024 | 3,705 | 43,736 (0%) | 0% | 43.8 | 162,464 | Common stock |
| Dr. Sarah Gheuens, M.D.,PhD | Chief Medical Officer | 01 Jul 2024 | 8,375 | 16,749 | - | - | Restricted stock units | ||
| Mr. Jeffrey D. Capello | Director | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | ||
| Mr. Jeffrey D. Capello | Director | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | ||
| Ms. Kaye Foster | Director | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | ||
| Ms. Kaye Foster | Director | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | ||
| Dr. Jacqualyn A. Fouse, PhD | Director | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | ||
| Ms. Cynthia Smith | Director | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | ||
| Ms. Cynthia Smith | Director | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | ||
| Dr. David P. Schenkein, M.D. | Director | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | ||
| Dr. David P. Schenkein, M.D. | Director | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | ||
| Dr. Maykin Ho, PhD | Director | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | ||
| Dr. Maykin Ho, PhD | Director | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | ||
| Dr. David T. Scadden, M.D. | Director | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | ||
| Dr. David T. Scadden, M.D. | Director | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | ||
| Dr. Rahul D. Ballal, PhD | Director | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | ||
| Dr. Rahul D. Ballal, PhD | Director | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | ||
| Mr. Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 1,976 | 1,976 (0%) | 0% | 0 | Common stock | |
| Mr. Jeffrey D. Capello | Director | 13 Jun 2024 | 1,976 | 3,953 | - | - | Restricted stock units | ||
| Ms. Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 8,912 (0%) | 0% | 0 | Common stock | |
| Ms. Kaye Foster | Director | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | ||
| Ms. Kaye Foster | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jun 2024 | 3,564 | 5,348 (0%) | 0% | 0 | Common stock | |
| Dr. Jacqualyn A. Fouse, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 140,784 (0%) | 0% | 0 | Common stock | |
| Dr. Jacqualyn A. Fouse, PhD | Director | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | ||
| Ms. Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 5,690 (0%) | 0% | 0 | Common stock | |
| Ms. Cynthia Smith | Director | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units |